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D iseases of the cardiovascular system remain a lead-ing cause of morbidity and mortality worldwide.1
Congestive heart failure is the only cardiovascular dis-
order increasing in prevalence.2 Quantitative deficiency
of cardiomyocytes and progressive ventricular remodel-
ing characterize the final pathway of heart failure
caused by various etiologies.3 Cellular cardiomyoplas-
ty4 (CCM), in which one delivers appropriate donor
cells into the injured myocardium, targets the basic
pathophysiology of heart failure and represents a novel
means of augmenting the myocyte number and the con-
tractile function of a failing heart. Data derived from
animal models have demonstrated the feasibility of this
approach,4-8 but the optimal choice of donor cell source
remains controversial.
Objectives: Marrow stromal cells are mesenchymal stem cells able to differ-
entiate into cardiomyocytes in vitro. We tested the hypothesis that marrow
stromal cells, when implanted into myocardium, can undergo milieu-depen-
dent differentiation and express cardiomyogenic phenotypes in vivo.
Methods: Isogenic adult rats were used as donors and recipients to simulate
autologous transplantation. Marrow stromal cells isolated from donor leg
bones were culture-expanded, labeled with 4´,6-diamidino-2-phenylindole,
and then injected into the myocardium of the recipients. The hearts were har-
vested from 4 days to 12 weeks after implantation, and the implant sites were
examined to identify the phenotypes of the labeled marrow stromal cells.
Results: Viable cells labeled with 4´,6-diamidino-2-phenylindole can be
identified in host myocardium at all time points after implantation.
Implanted marrow stromal cells show the growth potential in a myocardial
environment. After 4 weeks, donor cells derived from marrow stromal cells
demonstrate myogenic differentiation with the expression of sarcomeric
myosin heavy chain and organized contractile proteins. Positive staining for
connexin 43 indicates the formation of gap junctions, which suggests that
cells derived from marrow stromal cells, as well as native cardiomyocytes,
are connected by intercalated disks.
Conclusions: Different cell sources have been used as donor cells for cellular
cardiomyoplasty. Our findings indicate that marrow stromal cells can also be
used as donor cells. In an appropriate microenvironment they will exhibit
cardiomyogenic phenotypes and may replace native cardiomyocytes lost by
necrosis or apoptosis. Because marrow stromal cells can be obtained repeat-
edly by bone marrow aspiration and expanded vastly in vitro before being
implanted or used as autologous implants, and because their use does not call
for immunosuppression, the clinical use of marrow stromal cells for cellular
cardiomyoplasty appears to be most advantageous. (J Thorac Cardiovasc
Surg 2000;120:999-1006)
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Bone marrow stromal cells (MSCs), which are mes-
enchymal stem cells,9 have been shown to have the
potential of differentiating into cardiomyocytes in vitro
when treated with 5-azacytidine.10 Since autologous
MSCs can be obtained from patients by simple routine
bone marrow aspiration, and their use as donor cells
does not require fetal tissue or immunosuppression,
this approach appears to be highly advantageous for
clinical use.
In this study, we tested the hypothesis that MSCs
implanted into myocardium can undergo milieu-depen-
dent differentiation, form long-term grafts expressing
cardiomyogenic phenotypes, and be incorporated into
the host myocardium to form a syncytium.
Methods
Animals. Male inbred Lewis rats (200 to 250 g) were
obtained from Charles River Laboratories (Laprairie Co,
Quebec). These isogenic rats were used as donors and as
recipients to simulate autologous implantation clinically. All
animals received humane care in compliance with the “Guide
for the Care and Use of Laboratory Animals,” prepared by the
Institute of Laboratory Animal Resources, National Research
Council, and published by the National Academy Press
(revised 1996), and the “Guide to the Care and Use of
Experimental Animals” of the Canadian Council on Animal
Care.
Isolation and culture of MSCs. Isolation and primary cul-
ture of MSCs from the femoral and tibial bones of donor rats
were performed according to Caplan’s method.11 In brief,
after donor rats were killed with an overdose of pentobarbital
(100 mg/kg given intraperitoneally, MTC Pharmaceuticals,
Cambridge, Ontario, Canada), the femoral and tibial bones
were collected for isolation of MSCs. Cells isolated from
bone marrow in 10 mL of complete medium were then intro-
duced into tissue culture dishes. Medium was completely
replaced every 3 days, and the nonadherent cells were dis-
carded. Cultured MSCs were observed under phase micro-
scope to assess the level of expansion and to verify the mor-
phology at each culture medium change. To prevent the
MSCs from differentiating or slowing their rate of division,
each primary culture was replated (first passage) to 3 new
plates when the cell density within colonies became 80% to
90% confluent, approximately 2 weeks after seeding. The
adherent cells were released from the dishes with 0.25%
trypsin in 1 mmol/L sodium ethylenediaminetetraacetic acid
(Gibco Laboratories, Grand Island, NY), split 1:3, and seed-
ed onto fresh plates. After the twice-passaged cells became
nearly confluent, they were harvested and used for the
implantation experiments described below after being labeled
with 4´,6-diamidino-2-phenylindole (DAPI).
Medium. The cells were routinely cultured in complete
medium consisting of Dulbecco’s modified Eagle’s medium
containing selected lots of 10% fetal calf serum and antibi-
otics (100 U/mL of penicillin G, 100 µg/mL of streptomycin,
and 0.25 µg/mL of amphotericin B, from Gibco Laboratories)
at 37°C in a humidified atmosphere of 5% carbon dioxide.
MSC labeling. Sterile DAPI stock solution (Sigma, St
Louis, Mo) was added to the culture medium at a final con-
centration of 50 µg/mL on the day of implantation. The dye
was allowed to remain in the culture dishes for at least 30
minutes. The cells were rinsed at least 6 times in Hanks bal-
anced salt solution to remove all excess (unbound) DAPI.
Marrow stromal cells were then collected (approximately 1 ×
106 cells for one implantation) and resuspended in minimal
volume of the serum-free Dulbecco’s medium and stored on
ice (less than 1 hour) until implantation into the myocardium.
Implantation of MSCs. Anesthesia was induced and
maintained with isoflurane (Abbott Laboratories, St Laurent,
Quebec, Canada). The recipient animals’ lungs were intubat-
ed with an 18-gauge intravenous catheter and connected to a
Harvard rodent ventilator (Harvard Apparatus Co, South
Natick, Mass) to be ventilated at 85 breaths/min. The heart
was exposed through a 1.5-cm left thoracotomy incision.
Under direct vision, the MSC suspension was injected into
the left ventricular wall with a 28-gauge needle. The implan-
tation site was marked by 8-0 polypropylene sutures. The tho-
racotomy was closed with 4-0 monofilament sutures. The
muscle and skin layers were closed with 4-0 absorbable
sutures, and the animals were returned to their cages.
Histology and immunohistochemistry. Rats were killed
for the final experiments at the following intervals after the
cell implantation surgery: 4 days/4 rats, 2 weeks/2 rats, 4
weeks/4 rats, 6 weeks/4 rats, and 12 weeks/2 rats. After over-
dose with pentobarbital, the hearts were exposed and injected
with 100 mL of saline solution (0.9%) through the posterior
wall of the left ventricle, avoiding the transplant area, then
perfusion-fixed with 2% paraformaldehyde in phosphate-
buffered saline solution (PBS). The lateral wall of the left ven-
tricle was isolated from the remainder of the heart and was
either cryoembedded, after protection with 20% sucrose in
PBS, or embedded in paraffin. Sections 6 µm in thickness
were mounted on a set of gelatin-coated glass slides to ensure
different stains could be used on successive sections of tissue
cut through the implantation area. One of the sections was
mounted without stain, so the DAPI-labeled donor cells could
be located and viewed with fluorescence microscopy. An adja-
cent section was stained with hematoxylin and eosin to depict
nuclei, cytoplasm, and connective tissue. Other serial sections
were selected for immunostaining of sarcomeric myosin
heavy chain molecules with MF20 (Developmental Studies
Hybridoma Bank, University of Iowa, Iowa City, Iowa) or
connexin 43 with rabbit polyclonal antibody (Zymed
Laboratories Inc, San Francisco, Calif). These sections were
incubated in primary antibodies overnight at 4°C. For detec-
tion, we used secondary antibodies conjugated to Texas Red
for MF20 and fluorescein for anti-connexin 43 (Vector
Laboratories, Inc, Burlingame, Calif). Combined “DAPI and
Texas Red” or “DAPI and fluorescein” in images were made
by using a simultaneous excitation filter under reflected light
fluorescence microscopy (BX-FLA; Olympus  America, Inc,
1000 Wang et al The Journal of Thoracic and
Cardiovascular Surgery
November 2000
Huntington Station, NY). Digital images, transferred to a
computer equipped with Image Pro software (Media
Cybernetics, Silver Spring, Md), were subsequently printed
(Stylus Photo 700, Epson, Long Beach, Calif) for publication.
Results
Cultured MSCs were observed under phase
microscopy to assess the magnitude of expansion and
to verify the morphology at each culture medium
change. Most of the hematopoietic stem cells were not
adherent to the culture plate and were removed with
changes of medium. The adherent cells were seen as
individual cells or colonies of only a few cells on day
6; however, they replicated rapidly and formed colonies
of up to 100 cells after the first week of culture. By the
end of the second week, the colonies of adherent cells
had expanded in size, with each colony containing sev-
eral hundred to several thousand cells. Adherent MSCs
obtained from rat leg bone marrows had similar mor-
phology, most being fibroblastic, with a few adipocytic
polygonal cells (Fig 1). This phenotype was retained
throughout repeated passages under nonstimulating
conditions. Some adherent round cells were present but
normally accounted for less that 5% of the adherent
cell populations at the time cultures were ready to be
replated on first passage, and these cells further
reduced in frequency at the end of first and second pas-
sages. Since 3 new plates were generated by the replat-
ing of each near-confluent plate, a single primary cul-
ture generated 3 plates at first passage and 9 plates at
second passage. Since each near-confluent plate con-
tained on average 1.0 million cells, a single primary
culture starting with 100 to 500 adherent MSCs could
be expanded to well over 9.0 million cells by the sec-
ond passage. We labeled twice-passaged MSCs with
DAPI just before implantation surgery. The DAPI-
labeled MSCs showed clear nuclear and faint cytoplas-
mic blue fluorescence when viewed under an epifluo-
rescence microscope (Fig 2). Virtually 100% of the
cultured cells were labeled by DAPI.
Implantation mortality was zero after a period of
practice. All recipient rats survived to the time they
were killed. Gross examination of the specimen did not
reveal any structural abnormalities except sometimes a
tiny fibrotic change around implantation puncture sites
(marked by 8-0 suture). Paraffin sections as well as
frozen sections (for immunohistochemistry) of the
implant sites of the hearts were made to evaluate the
morphology and phenotype changes of implanted
MSCs. DAPI-labeled cells could be identified in all
specimens except 2 rats (one 6 weeks, the other 12
weeks) at all time points to at least 12 weeks after
surgery, the latest date assayed.
Four days after implantation numerous scattered
DAPI-labeled cells (blue fluorescence) were found in
the specimen (Fig 3, A). Hematoxylin and eosin stain-
ing of the consecutive section showed concordance
between dense hematoxylin staining and presence of
DAPI epifluorescence (Fig 3, B). The MSC-derived
donor cells showed an immature appearance with a
large nucleus-to-cytoplasm ratio. There was no obvious
inflammatory response at this time. Four weeks after
implantation, a few clearly DAPI-labeled cells were
found to be incorporated into the host myocardium (Fig
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Fig 1. The morphology of rat MSCs in in vitro culture. Phase
contrast photomicrograph of twice-passaged culture of MSCs
just before implantation. Most adherent MSCs are practically
fibroblastic in morphology. Scale bar represents 60 µm.
Fig 2. Labeling of rat MSCs in vitro before implantation into
the recipient rat hearts. DAPI epifluorescence (blue fluores-
cence) of twice-passaged culture of MSCs. Note the obvious
nuclear and faint cytoplasmic blue fluorescence. Virtually
100% of the cultured cells are labeled by DAPI. Scale bar
represents 30 µm.
4, A). They had abundant cytoplasm and had aligned
themselves with nonlabeled cells (host cardiomyo-
cytes). Hematoxylin and eosin stain of consecutive sec-
tion (Fig 4, B) showed that MSC-derived cells had the
same histologic appearance as those of surrounding
cardiomyocytes.
The phenotypes of implanted MSCs were confirmed
by means of immunohistochemistry. Fig 5 is taken from
a section of a heart 6 weeks after MSC implantation. We
used simultaneous excitation filter to combine DAPI
(blue fluorescence) and Texas Red (red fluorescence)
images of the same microscopic field. DAPI-labeled
cells (ie, MSC-derived) have centrally located nuclei
and were stained positive for sarcomeric myosin heavy-
chain molecules (with use of MF20 primary antibody
and Texas Red conjugated secondary antibody). The
surrounding host myocardium (nonlabeled cells) also
stained positive. These positively stained cells (MSC-
derived and host) had clear striations, which represent
organized contractile proteins. Again, DAPI-labeled
donor cells aligned in parallel with nonlabeled
myocytes (host cardiomyocytes) and were incorporated
into host myocardium. To further confirm the syncytial
incorporation of implanted MSCs with host cardiomy-
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Fig 3. MSC grafts in isogenic rat recipient hearts 4 days after implantation. A, DAPI epifluorescence (blue fluo-
rescence) photomicrographs. Note the numerous scattered DAPI-labeled cells present in this field. B, Hematoxylin
and eosin stain. Consecutive section to that shown in A. Note concordance between dense hematoxylin staining and
presence of DAPI epifluorescence. The labeled MSC-derived donor cells show immature appearance with large
nucleus-to-cytoplasm ratio. Scale bars represent 30 µm.
Fig 4. MSC grafts in isogenic rat recipient hearts 4 weeks after implantation. A, DAPI epifluorescence (blue fluo-
rescence) photomicrographs. Incorporation of DAPI-labeled cells with the host myocardium. B, Hematoxylin and
eosin stain. Consecutive section to that shown in A. Labeled MSC-derived cells have the same structure with that
of the surrounding cardiomyocytes. Asterisks show corresponding cross section of a blood vessel in this pair of
images (A and B). Scale bars represent 30 µm.
A B
A B
ocytes, and to elucidate the nature of the cell junction,
frozen sections were stained for connexin 43, one of gap
junction proteins in the intercalated disks, by using flu-
orescein conjugated secondary antibody. Again, by
using a simultaneous excitation filter, an image of com-
bined DAPI and fluorescein epifluorescence was
obtained from a section taken 6 weeks after the implan-
tation (Fig 6). Positive connexin 43 staining was found
at the interfaces of DAPI-labeled cells (MSC-derived)
and neighboring nonlabeled cells (host cardiomy-
ocytes), and between nonlabeled cells. The green fluo-
rescence of connexin 43 staining present along the axial
borders of the cells also showed the alignment of the
engrafted cells with surrounding cardiac myofibers.
Discussion
Deficiency of cardiomyocytes in different types of
heart failure may result from necrosis or from apopto-
sis.12 Myocardial regeneration and repair after injury is
severely limited by the inability of postembryonic heart
tissue to recruit muscle progenitor cells. Although ter-
minally differentiated cardiomyocytes have shown
some evidence of mitotic division in the adult heart,13
the rate of proliferation is minute and cannot meet the
demand for tissue regeneration. Therefore, efforts to
develop strategies to repair the injured myocardium for
treatment of heart failure are both rational and useful.
CCM, which uses the technique of cell transplantation
for myocardial regeneration, aims to replenish myocyte
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Fig 5. Expression of sarcomeric myosin heavy-chain mole-
cules of MSC-derived donor cells in specimens taken 6
weeks after implantation. Combined DAPI (blue fluores-
cence) and Texas Red (red fluorescence) images of the same
microscopic field. Arrow shows DAPI-labeled cell is posi-
tively stained with sarcomeric myosin heavy-chain immuno-
fluorescence (with use of MF20 primary antibody and Texas
Red conjugated secondary antibody), which shows clear stri-
ations. Scale bar represents 15 µm.
Fig 6. Expression of connexin 43 of MSC-derived donor cells
in a specimen 6 weeks after implantation. Combined DAPI
and fluorescein (green fluorescence) image. Anti-connexin
43 immunofluorescence is elicited, by using fluorescein con-
jugated secondary antibody. Positive connexin 43 staining
(arrowheads) is found at the interfaces between 1 DAPI-
labeled cell (arrow) and neighboring non-labeled cells (host
cardiomyocytes) and between non-labeled cells. Scale bar
represents 15 µm.
Table I. Major concerns about cell source in clinical application of cellular cardiomyoplasty
Cell source Ethical problem Acquirement concern Rejection Potential oncogenicity
Fetal cardiomyocytes Yes Yes Yes No
Adult cardiomyocytes No Yes No Yes
Skeletal myoblasts No Yes No No
Cell line cells No No Yes Yes
Embryonic stem cells Yes Yes Yes Yes
Marrow stromal cells No No No No
Acquirement concern includes logistic and other difficulties in getting donor cells, potentially irreversible injury to recipient/donor, and the difficulty in cultivating
and expanding cells in vitro.
number and thus represents a new strategy for treat-
ment of heart failure.
Different donor cell sources have been used experi-
mentally for CCM, and some investigators have report-
ed that CCM could improve the function of impaired
ventricle.6,7 However, each donor cell source, such as
fetal cardiomyocytes or skeletal myoblasts, appears to
encounter various ethical, biologic, or technical limita-
tions that must be overcome if it is to be considered for
application to human patients (Table I). MSCs are the
second group of stem cells, other than hematopoietic
stem cells in the bone marrow, with the capacity to dif-
ferentiate into cells that can roughly be defined as mes-
enchyma. Thus, they are also referred to as mesenchy-
mal stem cells.14 Under controlled in vitro conditions,
MSCs have been reproducibly guided to multiple mes-
enchymal lineages, including those of bone, cartilage,
adipocytes, myocytes, and even cardiomyocytes.10,15
We hypothesized that the myocardial microenviron-
ment would supply the proper conditions and signals
for the cardiomyogenic differentiation of MSCs. Thus,
transplanting MSCs into myocardium would induce
them through milieu-dependent differentiation to
develop into cardiomyocytes.
In this study, rat MSCs showed a capacity to prolifer-
ate in culture with an attached well-spread morphology
(Fig 1). We generated a morphologically homogeneous
phenotype population by serial passage of the cells
composing the adherent layer, and we removed most of
the hematopoietic stem cells using this method. We
successfully expanded MSCs from 500 to 9 million per
rat by about 14 cell doublings before implantation. This
feature holds great significance for clinical application
of CCM in terms of the number of cells needed to
improve cardiac function.16 In addition to the fact that
bone marrow aspiration is a simple and routine clinical
activity, this ability to cultivate and vastly multiply
MSCs in vitro should encourage the clinical use of this
cell source.
Experimentally, so the fate of the implanted cells
may be traced, MSCs are labeled while in culture with
DAPI. DAPI, a fluorescent dye, has been used as a cell
marker in study of cell biology.17 It labels the nucleus
of a cell because of a high affinity for dsDNA. Its
mechanism of action is that it forms strong electrostat-
ic interactions with adenine-thymine–rich regions of
DNA. The fluorescence quantum yield of the free dye
is very low, but the binding to DNA results in a highly
fluorescent complex.18 The other cell components to
which DAPI binds to form fluorescent complexes are
the protein tubulin and microtubules.19 DAPI is non-
toxic to living cells and does not alter the ultrastructure
of cell organelles. To further confirm the reliability of
this technique, we performed characterization in vitro
followed by in vivo analysis. Under the labeling con-
centration of 50 µg/mL for 30 minutes in culture, the
labeled cells show clear nuclear and faint cytoplasmic
staining and labeling efficiency is almost 100% (Fig 2).
There is no DAPI fluorescence detectable in the culture
medium. Our in vivo control studies, including injec-
tions into the myocardium of free DAPI solutions,
unlabeled MSCs or lysed DAPI-labeled MSCs while
performing the same epifluorescence read-out, con-
firmed the specificity of this cell labeling technique for
our study (data not shown).
Recently, Makino and associates10 could identify a
single clone of adherent fibroblast-like cells that
when treated with 5-azacytidine would differentiate
into cells with some morphologic features of cardiac
muscle and expression of cardiac-specific genes.
Tomita and colleagues20 transplanted fresh, cultured,
and 5-azacytidine–treated bone marrow cells into the
cryoinjury scar in a rat model and reported car-
diomyogenic differentiation with expression of car-
diac specific protein, troponin I. Our results further
demonstrated that the myocardial microenvironment
could support the growth and induce the cardiomyo-
genic differentiation of MSCs after their implanta-
tion. The mechanisms and the signals to induce
MSC-derived donor cells to undergo cardiomyogenic
differentiation within the myocardial environment
are not fully understood. Recent studies have led to
the suggestion that the MSCs may act as cycling stem
cells and that they are involved in the mesengenic
process for self-maintenance and repair of different
mesenchymal tissues after birth.21 Moreover, the
progeny of MSCs expressed genes in a tissue-specif-
ic manner according to the destination to which they
arrived.22 This homing ability and the ability to
acquire the phenotypes of different target tissues sug-
gest the microenvironment plays a significant role on
the differentiation of these cells. On the basis of
recent studies on stem cell biology and differentia-
tion, it is assumed that specific molecules, growth
factors, cytokines, and interactions among stem cells,
host cells, and extracellular matrix are necessary, and
they are presented to the stem cells in a temporal and
sequential manner in order to induce the expression
of related developmental genes in sequence and dri-
ving their differentiation into different tissues.23,24
We suggest that the normal myocardial microenvi-
ronment may supply the proper mix and sequential
exposure to the cardiomyogenic specific growth fac-
tors and differentiation molecules, so that the
implanted MSCs could develop to fully mature car-
diomyocytes.
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We also demonstrated that these MSC-derived donor
cells are not only myogenically differentiated but also
developed mature organized contractile protein. In
addition, they connected and aligned with host car-
diomyocytes by gap junctions. The intact heart is a
syncytium with an elaborate three-dimensional
myocardial orientation and specialized cell junctions.25
This organization ensures the orderly propagation of
electrical signals and the coordinated contraction of the
myocardium. In CCM, implanted cells are used to per-
form specific physiologic roles, and thus the pheno-
types and the maturation of the cells and their spatial
location in relation to the host myocardial supracellular
organization are critical to their application. These 2
characteristics of MSC-derived donor cells found in
this study are prerequisites for implanted donor cells to
improve the contractile function of recipient hearts.
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Discussion
Dr Shinji Tomita (Toronto, Ontario, Canada). We are also
involved in cell transplantation, especially using bone mar-
row.1 I want to ask Dr Wang several questions. First, what
percentage of the transplanted cells are going to differentiate
into cardiomyogenic cells? Next, what is the possible factor
regarding the cardiac milieu? Is that like pressure or growth
factor?
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Dr Wang. Thank you for your question. We did not calcu-
late the percentage of the cells that change to cardiomyocytes,
although we did find that DAPI-labeled cells decreased sig-
nificantly after 4 weeks in our specimen.
As to the other question, about the milieu-dependent dif-
ferentiation, intuitively we think the myocardial environment
may supply the proper mix and the sequential exposure of
cardiomyogenic specific growth factor and differentiation
molecules to the implanted marrow stromal cells. So we also
think that a microenvironment is very important. We are now
focusing on the microenvironment issue. We are trying to
evaluate the impact of different microenvironments on these
cells’ differentiation.
Dr Yasuharu Noishiki (Yokohama, Japan). I have a differ-
ent opinion related to the marrow cell transplantation.
Because marrow cells are very young and primitive, they
want to survive when they are transplanted into a different
environment. When we transplant marrow cells, we can see
the many angiogenic growth factors synthesized around the
cells. So we can observe capillary ingrowth around the site.
Do you have any data similar to these?
Dr Wang. Thank you for your question. We have no data
now about angiogenesis, but for cellular cardiomyoplasty we
still need to answer some issues—for example, if these cells
can engraft in the ischemic myocardium or myocardial scar.
The other question is if the cellular cardiomyoplasty itself
can induce angiogenesis. We have no data for this now.
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